The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Increases speed to market for drug developers working on nucleic acid therapeutics
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
ICMR will continue to track trends in HMPV circulation throughout the year
Brings together industry experts to discuss preventive steps to protect pigs from African swine fever and best practises for pig farm management
Subscribe To Our Newsletter & Stay Updated
